For the quarter ending 2025-09-30, REVBW had $7,534,618 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,907,176 | -4,495,467 |
| Stock-based compensation expense | 874 | 224,328 |
| Depreciation expense | 6,765 | 14,441 |
| Loss on disposal of equipment | -11,207 | - |
| Change in fair value of warrant liability | -611 | -1,460 |
| Prepaid expenses and other current assets | -62,115 | 119,350 |
| Accounts payable | 191,057 | 45,273 |
| Disposal of lab supplies | - | 6,721 |
| Accrued expenses | 53,589 | -388,174 |
| Net cash used in operating activities | -1,588,901 | -4,713,688 |
| Proceeds from public offering, net-May2025Public Offering | 0 | 3,388,244 |
| Proceeds from warrant exercise-Class HPre Funded Warrants | 0 | 297 |
| Proceeds from warrant exercise-Warrant Inducement | 8,760,519 | - |
| Proceeds from warrant exercise-Class HWarrants | 363,000 | - |
| Net cash provided by financing activities | 9,123,519 | 3,388,541 |
| Net increase (decrease) in cash and cash equivalents | 7,534,618 | -1,325,147 |
| Cash and cash equivalents at beginning of period | 6,499,018 | - |
| Cash and cash equivalents at end of period | 12,708,489 | - |
REVELATION BIOSCIENCES, INC. (REVBW)
REVELATION BIOSCIENCES, INC. (REVBW)